Obodence |
Human |
denosumab |
denosumab |
EMEA/H/C/006424 |
Samsung Bioepis NL B.V. |
2025/02/12
|
Authorised |
Zefylti |
Human |
filgrastim |
filgrastim |
EMEA/H/C/006400 |
CuraTeQ Biologics s.r.o |
2025/02/12
|
Authorised |
Emcitate |
Human |
tiratricol |
tiratricol |
EMEA/H/C/005220 |
Rare Thyroid Therapeutics International AB |
2025/02/12
|
Authorised |
Welireg |
Human |
belzutifan |
belzutifan |
EMEA/H/C/005636 |
Merck Sharp & Dohme B.V. |
2025/02/12
|
Authorised |
Nemluvio |
Human |
nemolizumab |
nemolizumab |
EMEA/H/C/006149 |
Galderma International |
2025/02/12
|
Authorised |
Korjuny |
Human |
catumaxomab |
catumaxomab |
EMEA/H/C/005697 |
Atnahs Pharma Netherlands B.V. |
2025/02/10
|
Authorised |
Andembry |
Human |
garadacimab |
garadacimab |
EMEA/H/C/006116 |
CSL Behring GmbH |
2025/02/10
|
Authorised |
Beyonttra |
Human |
acoramidis |
acoramidis hydrochloride |
EMEA/H/C/006333 |
BridgeBio Europe B.V. |
2025/02/10
|
Authorised |
Hetronifly |
Human |
serplulimab |
Serplulimab |
EMEA/H/C/006170 |
Accord Healthcare S.L.U. |
2025/02/03
|
Authorised |
Kavigale |
Human |
sipavibart |
sipavibart |
EMEA/H/C/006291 |
AstraZeneca AB |
2025/01/20
|
Authorised |
Lazcluze |
Human |
lazertinib |
lazertinib mesilate monohydrate |
EMEA/H/C/006074 |
Janssen Cilag International NV |
2025/01/20
|
Authorised |
Ahzantive |
Human |
aflibercept |
aflibercept |
EMEA/H/C/006607 |
Formycon AG |
2025/01/13
|
Authorised |
Siiltibcy |
Human |
Mycobacterium tuberculosis derived antigens (rdESAT-6 / rCFP-10) |
Mycobacterium tuberculosis derived antigens (rdESAT‑6 and rCFP‑10) |
EMEA/H/C/006177 |
Serum Life Science Europe GmbH |
2025/01/13
|
Authorised |
Baiama |
Human |
aflibercept |
aflibercept |
EMEA/H/C/005980 |
Formycon AG |
2025/01/13
|
Authorised |
Gohibic |
Human |
vilobelimab |
vilobelimab |
EMEA/H/C/006123 |
InflaRx GmbH |
2025/01/13
|
Authorised |
Augtyro |
Human |
repotrectinib |
repotrectinib |
EMEA/H/C/006005 |
Bristol-Myers Squibb Pharma EEIG |
2025/01/13
|
Authorised |
Buprenorphine Neuraxpharm |
Human |
buprenorphine |
Buprenorphine hydrochloride |
EMEA/H/C/006188 |
Neuraxpharm Pharmaceuticals S.L. |
2024/12/19
|
Authorised |
Alhemo |
Human |
concizumab |
concizumab |
EMEA/H/C/005938 |
Novo Nordisk A/S |
2024/12/13
|
Authorised |
Eltrombopag Viatris |
Human |
eltrombopag |
eltrombopag olamine |
EMEA/H/C/006417 |
Viatris Limited |
2024/12/12
|
Authorised |
Imuldosa |
Human |
ustekinumab |
ustekinumab |
EMEA/H/C/006221 |
Accord Healthcare S.L.U. |
2024/12/12
|
Authorised |